# Plasma lipidomics, choline metabolites, and metabolic-associated steatotic liver disease (MASLD): A Coronary Artery Risk Development in Young Adults (CARDIA) study

**Authors:** Jessica K. Sprinkles, Qiyao Qin, Charles Steward, Annie Green Howard, Anju Lulla, Autumn G. Hullings, J Jeffrey Carr, Saame Raza Shaikh, Christy L. Avery, Kari E. North, Penny Gordon-Larsen, Katie A. Meyer

PMC · DOI: 10.1371/journal.pone.0341462 · PLOS One · 2026-03-13

## TL;DR

This study explores how plasma lipids and choline metabolites are linked to liver disease in a large group of young adults.

## Contribution

The study provides population-based evidence linking lipidomics and choline metabolites to MASLD, highlighting FA composition's role.

## Key findings

- Total TAGs, DAGs, and DCERs were positively associated with MASLD, while LCERs were inversely associated.
- Betaine was inversely associated with MASLD in choline metabolite models.
- A lipidomic risk score linked choline positively and betaine inversely to MASLD.

## Abstract

Metabolic-associated steatotic liver disease (MASLD) is marked by accumulation of hepatic triacylglycerols (TAG), but many other lipids have been implicated. Choline metabolism has been shown to be related to MASLD, specifically through phosphatidylcholines (PC) role in hepatic TAG removal through very low density lipoproteins (VLDL). There are a lack of population-based studies with integrated data on lipidomics, choline metabolites, and MASLD. We tested associations between the plasma lipidome, choline metabolites, and MASLD using data from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. The analytic sample included 1,039 participants with data on choline metabolite, lipidomic, and liver attenuation data [mean (SD) age: 45 (4); 57% female; 57% White race]. MASLD (n = 234) was defined as mean CT-derived liver attenuation < 51HU. Plasma lipidomics and choline metabolites were quantified from stored fasting plasma using liquid-chromatography and infusion-mass spectrometry. In logistic regression adjusted for sociodemographics, lifestyle, and clinical variables, total TAGs, diacylglycerols (DAG), and dihydroceramides (DCER) were positively, and lactosylceramides (LCER) were inversely, associated with MASLD. Species-level results revealed diverging MASLD associations for PCs, based on FA composition. In choline metabolite models, betaine was inversely associated with MASLD. A lipidomic risk score (LRS) derived from penalized regression of MASLD on lipid species was associated positively with choline, and inversely with betaine. We contribute population-based results to a growing literature relating lipidomics and MASLD. In our data, FA composition is biologically relevant to MASLD, particularly for PCs and TAGs. Our results link choline metabolites to both the plasma lipidome and to incident MASLD, furthering efforts in biomarker development and supporting mechanistic evidence using population-level data.

## Linked entities

- **Chemicals:** phosphatidylcholines (PubChem CID 24778708), triacylglycerols (PubChem CID 5460048), diacylglycerols (PubChem CID 6026790), betaine (PubChem CID 247), choline (PubChem CID 305)
- **Diseases:** MASLD (MONDO:0013209)

## Full-text entities

- **Genes:** PC (pyruvate carboxylase) [NCBI Gene 5091] {aka PCB}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** CARDIAs (MESH:D004938), hepatocellular carcinoma (MESH:D006528), diabetes (MESH:D003920), Coronary Artery (MESH:D003324), HIV (MESH:D015658), insulin resistance (MESH:D007333), Obesity (MESH:D009765), T2D. (MESH:D003924), NAFLD (MESH:D065626), MASLD (MESH:D008107), lipid (MESH:D011017), Hypertension (MESH:D006973), cardiometabolic diseases (MESH:D024821), liver dysfunction (MESH:D017093), Chronic Kidney Disease (MESH:D051436), fatty liver (MESH:D005234), inflammation (MESH:D007249), hepatitis (MESH:D056486), cirrhosis (MESH:D005355), CARDIA (MESH:C563569)
- **Chemicals:** alcohol (MESH:D000438), sphingomyelin (MESH:D013109), TAG (MESH:D014280), valproate (MESH:D014635), LIPID (MESH:D008055), lysophospholipids (MESH:D008246), amiodarone (MESH:D000638), SM (MESH:D012493), DAG diacylglycerol (-), cholesterol (MESH:D002784), LCER (MESH:D007790), lysophosphatidylethanolamines (MESH:C008301), carbon (MESH:D002244), FA (MESH:D005227), DCERs (MESH:C067541), phosphatidylethanolamine (MESH:C483858), Choline (MESH:D002794), DCER (MESH:C109343), tamoxifen (MESH:D013629), betaine (MESH:D001622), monoacylglycerols (MESH:D050178), Silica (MESH:D012822), free fatty acids (MESH:D005230), ammonium acetate (MESH:C018824), nitrogen (MESH:D009584), CE (MESH:D002563), phosphatidylethanolamines (MESH:D010714), CER (MESH:D002518), FA (MESH:D005492), creatinine (MESH:D003404), PC (MESH:D010713), unsaturated fatty acids (MESH:D005231), cholesteryl esters (MESH:D002788), TMAO (MESH:C005855), methanol (MESH:D000432), methotrexate (MESH:D008727), lysophosphatidylcholines (MESH:D008244), dichloromethane (MESH:D008752), DAG (MESH:D004075), phospholipid (MESH:D010743), PEEK (MESH:C063834), PI (MESH:D010716)
- **Species:** Homo sapiens (human, species) [taxon 9606], Gallus gallus (bantam, species) [taxon 9031], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987446/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12987446/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987446/full.md

---
Source: https://tomesphere.com/paper/PMC12987446